Madeline Zech Ruiz discusses the reception to her book on urology

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

To investigate the severity and prevalence of dermatologic adverse events associated with apalutamide, Mario E. Lacouture, MD, and investigators conducted a study that will help to manage and counsel patients with prostate cancer in the future, especially with the expanded approval of apalutamide in this space.

In a recent interview, Hossein Jadvar, MD, PhD, discussed what the appropriate use criteria consist of for prostate-specific membrane antigen (PSMA)-PET imaging, and why these criteria are vital in ensuring the individualized care of patients.

"Certainly, the Optilume drug-coated balloon appears to be safe and effective in roughly two-thirds of patients at 3 years," said Justin Chee, MD.

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.